Answers are grounded in this paper and cite their sources.
The degradation scheme of stabilized and non‐stabilized (solubility criteria) human fibrin clots, as obtained by porcine plasmin and urokinase activation of human plasminogen, is illustrated by crossed immuno‐electrophoresis in agarose using antifibrinogen and monospecific anti‐D and anti‐E serum and is further characterized by Sephadex G 150 filtration and by sodium dodecyl sulphate polyacrylamide electrophoresis. Heat labile E‐antigenic fractions exhibiting slow migration in agarose appear early during digestion of fibrin and are especially characteristic for the degradation of stabilized fibrin, whereas only traces are found during degradation of non‐stabilized fibrin. They decrease in concentration and disappear as the final E‐antigenic fraction with distinct anodic mobility in agarose develops. The intermediary fractions are eluted by Sephadex G 150 filtration before the final plasmin resistant E‐fraction. Some of these intermediates may have a molecular weight from more than 50, 000 to around 250, 000, whereas the final E‐antigenic plasmin resistant has a molecular weight of 50, 000. The plasmin‐resistant heat‐labile D‐fragments found during digestion of non‐stabilized fibrin have a molecular weight of around 100, 000, whereas plasmin‐resistant D‐antigenic fractions found during degradation of stabilized fibrin have a molecular weight of around 190, 000, all molecular weights approximated (non‐reduced freeze dried Sephadex filtrates).
No takes yet. Share an insight, caveat, or question.
Gormsen et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: